S&CO Inc. Acquires 12,120 Shares of Edwards Lifesciences Co. (NYSE:EW)

S&CO Inc. boosted its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 24.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,555 shares of the medical research company's stock after purchasing an additional 12,120 shares during the quarter. S&CO Inc.'s holdings in Edwards Lifesciences were worth $4,062,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in EW. Bank of New York Mellon Corp lifted its position in Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company's stock valued at $1,827,347,000 after acquiring an additional 809,605 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company's stock worth $622,695,000 after purchasing an additional 2,390,137 shares in the last quarter. AustralianSuper Pty Ltd grew its stake in shares of Edwards Lifesciences by 17.8% in the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company's stock worth $216,013,000 after buying an additional 494,604 shares during the last quarter. Ownership Capital B.V. increased its position in Edwards Lifesciences by 1.2% during the 3rd quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company's stock valued at $197,509,000 after buying an additional 34,597 shares in the last quarter. Finally, Champlain Investment Partners LLC raised its stake in Edwards Lifesciences by 3.1% during the first quarter. Champlain Investment Partners LLC now owns 2,964,168 shares of the medical research company's stock valued at $283,256,000 after buying an additional 88,205 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. The Goldman Sachs Group reduced their price target on Edwards Lifesciences from $107.00 to $91.00 and set a "buy" rating for the company in a report on Friday, July 26th. Bank of America cut shares of Edwards Lifesciences from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $105.00 to $75.00 in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a "buy" rating on the stock in a research note on Thursday, July 25th. Royal Bank of Canada reduced their price target on shares of Edwards Lifesciences from $85.00 to $75.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Finally, Barclays lowered their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $75.67.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded up $1.60 during midday trading on Friday, hitting $67.76. The stock had a trading volume of 7,530,072 shares, compared to its average volume of 5,248,893. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a market capitalization of $39.96 billion, a PE ratio of 9.78, a P/E/G ratio of 3.81 and a beta of 1.12. The firm's fifty day moving average is $67.44 and its two-hundred day moving average is $76.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.59 earnings per share. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company's stock, valued at $2,051,843.35. This represents a 4.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,250 shares of company stock worth $2,744,438 over the last ninety days. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.